Prognostic stratification and treatment of cardiac light chain amyloidosis: A narrow path in the jungle

Journal of Heart and Lung Transplantation

Volumn 33, Issue 2, 2014, Pages 136-138

  Potena, Luciano ^a   Quarta, Candida Cristina ^a   Grigioni, Francesco ^a   Rapezzi, Claudio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; TROPONIN C; TROPONIN I;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BODY MASS; CARDIAC LIGHT CHAIN AMYLOIDOSIS; HEART AMYLOIDOSIS; HEART FAILURE; HEART TRANSPLANTATION; HEART VENTRICLE PRESSURE; HUMAN; MORTALITY; NOTE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RESTRICTIVE CARDIOMYOPATHY; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; TREATMENT OUTCOME;

AMYLOIDOSIS; BODY MASS INDEX; CARDIOMYOPATHIES; FEMALE; HEART DISEASES; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; MALE;

EID: 84893416793     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2013.11.007     Document Type: Editorial

References (20)

1. E. Desport, F. Bridoux, and C. Sirac et al. Al amyloidosis Orphanet J Rare Dis 7 2012 54
2. G. Merlini, and G. Palladini Light chain amyloidosis: the heart of the problem Haematologica 98 2013 1492 1495
3. M.A. Gertz, R. Comenzo, and R.H. Falk et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004 Am J Hematol 79 2005 319 328
4. S. Dinner, W. Witteles, and A. Afghahi et al. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement Haematologica 98 2013 1593 1599
5. L.G. Gilstrap, E. Niehaus, and R. Malhotra et al. Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis J Heart Lung Transplant 33 2013 149 156
6. S.W. Dubrey, M.M. Burke, P.N. Hawkins, and N.R. Banner Cardiac transplantation for amyloid heart disease: the United Kingdom experience J Heart Lung Transplant 23 2004 1142 1153
7. M.Q. Lacy, A. Dispenzieri, and S.R. Hayman et al. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy J Heart Lung Transplant 27 2008 823 829
8. B.R. Dey, S.S. Chung, and T.R. Spitzer et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure Transplantation 90 2010 905 911
9. M.S. Maurer, A. Raina, and C. Hesdorffer et al. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure Transplantation 83 2007 539 545
10. E.C. DePasquale, K. Nasir, and D.L. Jacoby Outcomes of adults with restrictive cardiomyopathy after heart transplantation J Heart Lung Transplant 31 2012 1269 1275
11. P.T. Sattianayagam, T. Lane, and Z. Fox et al. A prospective study of nutritional status in immunoglobulin light chain amyloidosis Haematologica 98 2013 136 140
12. A. Dispenzieri, M.A. Gertz, and R.A. Kyle et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis J Clin Oncol 22 2004 3751 3757
13. A.D. Wechalekar, S.O. Schonland, and E. Kastritis et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis Blood 121 2013 3420 3427
14. A. Jaccard, P. Moreau, and V. Leblond et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis N Engl J Med 357 2007 1083 1093
15. Y. Topilsky, N.L. Pereira, and D.K. Shah et al. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy Circ Heart Fail 4 2011 266 275
16. J. Guan, S. Mishra, and J. Shi et al. Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity Basic Res Cardiol 108 2013 378
17. K. Bodin, S. Ellmerich, and M.C. Kahan et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits Nature 468 2010 93 97
18. D. Mereles, S.J. Buss, S.E. Hardt, W. Hunstein, and H.A. Katus Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis Clin Res Cardiol 99 2010 483 490
19. L.W. Stevenson The urgent priority for transplantation is to trim the waiting list J Heart Lung Transplant 32 2013 861 867
20. M.R. Mehra, J. Kobashigawa, and R. Starling et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates - 2006 J Heart Lung Transplant 25 2006 1024 1042